A Study to Investigate the Safety of AZD6750
Phase 1/2
60
about 4.2 years
18+
6 sites in MI, MO, PA +2
What this study is about
Researchers are testing the safety of a treatment called AZD6750 in adults with certain advanced or metastatic solid tumors. The trial will last for about 1 year and involve approximately 60 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AZD6750
- 2.Take rilvegostomig
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: PK Area Under Curve (AUC)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), PK Clearance- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), PK Half-life- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), PK Maximum plasma concentration (Cmax)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), PK Minimum observed concentration (Cmin)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), PK Time to maximum plasma concentration (tmax)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), Pharmacodynamic- Part 1A & Part 2A (dose escalation) and Part B (dose expansion)
Oncology